Insider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 9,621 Shares of Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder George Jay Goldsmith sold 9,621 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $8.29, for a total value of $79,758.09. Following the completion of the sale, the insider now owns 3,966,052 shares in the company, valued at approximately $32,878,571.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Tuesday, April 16th, George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93.
• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.96, for a total transaction of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20.

COMPASS Pathways Stock Up 0.9 %

CMPS stock traded up $0.08 during midday trading on Monday, reaching $8.61. 189,012 shares of the company were exchanged, compared to its average volume of 662,041. The company has a market cap of $533.30 million, a price-to-earnings ratio of -3.60 and a beta of 2.39. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. COMPASS Pathways plc has a 1-year low of $5.01 and a 1-year high of $12.75. The stock’s 50-day simple moving average is $9.51 and its 200 day simple moving average is $8.51.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, equities analysts forecast that COMPASS Pathways plc will post -2.4 earnings per share for the current year.

Institutional Trading of COMPASS Pathways

A number of large investors have recently made changes to their positions in CMPS. Quest Partners LLC purchased a new stake in COMPASS Pathways in the fourth quarter valued at approximately $33,000. Conservest Capital Advisors Inc. purchased a new position in shares of COMPASS Pathways during the fourth quarter worth about $91,000. Bailard Inc. acquired a new position in COMPASS Pathways in the 3rd quarter valued at about $88,000. EWA LLC acquired a new position in COMPASS Pathways in the 4th quarter valued at about $107,000. Finally, TAP Consulting LLC raised its stake in COMPASS Pathways by 14.7% during the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock valued at $95,000 after acquiring an additional 1,645 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CMPS. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research note on Friday, March 1st. Morgan Stanley started coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Tuesday, April 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $47.40.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.